AKBA Stock Recent News

AKBA LATEST HEADLINES

AKBA Stock News Image - prnewswire.com

CAMBRIDGE, Mass. , June 3, 2024 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 4 newly-hired employees options to purchase an aggregate of 76,000 shares of Akebia's common stock on May 31, 2024, as inducements material to such employee entering into employment with Akebia.

prnewswire.com 2024 Jun 03
AKBA Stock News Image - prnewswire.com

CAMBRIDGE, Mass. , May 23, 2024 /PRNewswire/ --  Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present at the Jefferies Global Healthcare Conference on Wednesday, June 5 at 9:00 a.m.

prnewswire.com 2024 May 23
AKBA Stock News Image - Zacks Investment Research

Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.09 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.14 per share a year ago.

Zacks Investment Research 2024 May 09
AKBA Stock News Image - PRNewsWire

Akebia to Host Conference Call on May 9, 2024, at 8:00 a.m. ET CAMBRIDGE, Mass.

PRNewsWire 2024 May 02
AKBA Stock News Image - MarketBeat

Akebia Therapeutics Inc. NASDAQ: AKBA is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia management for patients with CKD. The medical sector company addresses unmet needs in the segment.

MarketBeat 2024 Apr 03
AKBA Stock News Image - Zacks Investment Research

Akebia (AKBA) gains during premarket hours on Mar 28 as its key product Vafseo (vadadustat) tablets receive FDA's approval for the treatment of anemia due to chronic kidney disease.

Zacks Investment Research 2024 Mar 28
AKBA Stock News Image - Reuters

The U.S. Food and Drug Administration approved Akebia Therapeutics' drug to treat anemia caused by chronic kidney disease in dialysis patients, the drugmaker said on Wednesday.

Reuters 2024 Mar 27
AKBA Stock News Image - Zacks Investment Research

Akebia Therapeutics (AKBA) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.04 per share a year ago.

Zacks Investment Research 2024 Mar 14
AKBA Stock News Image - PRNewsWire

CAMBRIDGE, Mass. , March 11, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to report fourth quarter and full year 2023 financial results on March 14, 2024.

PRNewsWire 2024 Mar 11
AKBA Stock News Image - PRNewsWire

CAMBRIDGE, Mass. , Nov. 20, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28 th at 10:30 a.m.

PRNewsWire 2023 Nov 20
10 of 50